<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-25-097130</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Nantahala Capital Partners Limited Partnership -->
          <cik>0001502725</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.01 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0000318306</issuerCik>
        <issuerName>ABEONA THERAPEUTICS INC.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>00289Y206</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>6555 Carnegie Avenue, 4thFloor</com:street1>
          <com:city>Cleveland</com:city>
          <com:stateOrCountry>OH</com:stateOrCountry>
          <com:zipCode>44103</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP</reportingPersonName>
      <citizenshipOrOrganization>MA</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>3333757.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>3333757.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3333757.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.82</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ABEONA THERAPEUTICS INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>6555 Carnegie Avenue, 4thFloor Cleveland, OH, 44103</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP ("Nantahala")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>130 Main St. 2nd Floor, New Canaan, CT 06840</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Nantahala is a Massachusetts limited partnership.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>As of March 31, 2026, Nantahala may be deemed to be the beneficial owner of 3,333,757 Shares. The 3,333,757 Shares includes 179,832 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of securities.</amountBeneficiallyOwned>
        <classPercent>As of March 31, 2026 each of the Reporting Persons may be deemed to be the beneficial owner of 5.82% of the total number of Shares outstanding, based on 57,049,023 shares outstanding  from the December 31, 2025 10-Q in addition to 179,832 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of securities.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>3,333,757</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>3,333,757</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Taki Vasilakis</signature>
        <title>Taki Vasilakis / Chief Compliance Officer Nantahala Capital Management, LLC</title>
        <date>05/15/2026</date>
      </signatureDetails>
      <signatureDetails>
        <signature>/s/ Wilmot B. Harkey</signature>
        <title>Wilmot B. Harkey / Manager Nantahala Capital Management, LLC</title>
        <date>05/15/2026</date>
      </signatureDetails>
      <signatureDetails>
        <signature>/s/ Daniel Mack</signature>
        <title>Daniel Mack / Manager Nantahala Capital Management, LLC</title>
        <date>05/15/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
